Merging molecular and systems neuroscience to uncover the ground rules of behaviors. UCSD Professor & HHMI Investigator. Redpin cofounder. World IPA tourist.
As a medical technology, CGT (cell and gene therapy) can conduct IITs (investigator-initiated trials) even before the product is approved for market — it only needs to be filed with the hospital's supervising authority, registered on ChiCTR, and approved by the hospital's ethics committee.
This creates a regulatory gap. The "Order 818" policy, which took effect May 1 this year, has tightened oversight of this type trials to some extent.
Of course, CGTs also can be as drug to file IND applications to NMPA, and conduct registratory study and approved as drugs.
For non-medical-technology drugs, however, IITs still require NMPA market approval first — for example, real-world studies exploring expanded indications.
Separately, Hainan's Boao Lecheng pilot zone serves as a testing ground, allowing products already approved overseas but not yet approved by the NMPA to be used in designated pilot hospitals after approvals within the zone, enabling real-world studies to be conducted there.
As a medical technology, CGT (cell and gene therapy) can conduct IITs (investigator-initiated trials) even before the product is approved for market — it only needs to be filed with the hospital's supervising authority, registered on ChiCTR, and approved by the hospital's ethics committee.
This creates a regulatory gap. The "Order 818" policy, which took effect May 1 this year, has tightened oversight of this type trials to some extent.
Of course, CGTs also can be as drug to file IND applications to NMPA, and conduct registratory study and approved as drugs.
For non-medical-technology drugs, however, IITs still require NMPA market approval first — for example, real-world studies exploring expanded indications.
Separately, Hainan's Boao Lecheng pilot zone serves as a testing ground, allowing products already approved overseas but not yet approved by the NMPA to be used in designated pilot hospitals after approvals within the zone, enabling real-world studies to be conducted there.
@michaelzlin Exactly. The key is to see if it helps patients. The people at Redoin and Kriya did an amazing job and I am grateful to the investors for taking this on. This was a complicated problem to solve over many steps for creating the pathway to do this in people.
The risk adjusted economic issues partly come from uncertainty about regulatory path. Small molecule + gene therapy was not an established path with regulators. Our PSAM/varenicline chemogenetics had green light in 2023 but trial finally started this year https://t.co/lbSjD27hJi
For years I’ve been asking my neuro colleagues why we hadn’t done clinical chemogenetics yet. Most said too pricey small or risky. Yet clearly the tech and the need are there.
My take: VCs in the US are too big now — only social media (prev) or AI (now) have the scale they want.
Worth noting that over $100M was invested into chemogenetics in the US based on two companies: Redpin and CODA. CODA tried to replicate Redpin’s technology but ran out of time and money. Redpin was acquired by Kriya and the Redpin tech (developed by my lab) is in clinical trial.
For years I’ve been asking my neuro colleagues why we hadn’t done clinical chemogenetics yet. Most said too pricey small or risky. Yet clearly the tech and the need are there.
My take: VCs in the US are too big now — only social media (prev) or AI (now) have the scale they want.
@zenbrainest Sponsor is Kriya Therapeutics (a North Carolina company) who acquired Redpin Therapeutics, which was the company I co-founded to develop human therapeutic chemogenetics. So, I am no longer involved in the development process and do not have any non-public information.
Not mentioned was the ongoing chemogenetic trial in North America! https://t.co/lbSjD27hJi
PSAM4-GlyR chemogenetic system in combination with varenicline for neuropathic facial pain
Some pics from @cpnoct, @adhikari, and @BrainCaRMA's visit to Seoul. Learned so much at both SNU Symposium on Neural Circuits for Thermoregulation (and feeding behavior ;) + #icomes2025. Thanks for inspiring science, great conversations, and fun times!
1/ 🧬 The Cocaine Cure
What if the same drug that hijacks your brain could be used to treat its own addiction?
Scientists are engineering ion channels that only turn on in the presence of cocaine, flipping the reward circuit on its head.
Here’s how it works, and why it matters 👇🏼
🤠Be sure to read to the end if you are also into Fentanyl and Meth
We used protein engineering to develop cocaine-gated ion channels. Our approach simplifies chemogenetic applications for cocaine addiction by having cocaine itself activate inhibitory and/or excitatory channels. Collaboration between @mikelides@BrainCaRMA https://t.co/X4zUdhGUG2
Two papers that very nicely show effectiveness of PSAM4-GlyR chemogenetics in concert with FDA-approved varenicline or more selective uPSEM792 in pain animal models as well as in IPSC-derived human sensory neurons. https://t.co/PqS6tiCY75
Eugene Myers @TheGeneMyers, Director Emeritus & research group leader @mpicbg & @csbdresden was honored with the @Caltech Distinguished Alumni Award. He receives recognition for having revolutionized the bioinformatics industry. Congratulations! 🎉https://t.co/1YHuydl969